Organon & Co. Common Stock (OGN)

FairStock Score: 52/100 — MIXED

Key Financials

Strengths

• Generates $190 million in annual free cash flow (8.5% yield on market cap)
• High return on equity of 30.6% demonstrating efficient capital deployment

Concerns

• High leverage at 11.70x debt-to-equity increases financial risk and interest expense burden
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 5.3% year-over-year signals potential demand weakness or market share loss
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Organon & Co. Common Stock is a small-cap healthcare company valued at $2.2 billion. Revenue stands at $6.2 billion, though the company is currently unprofitable. From a quality standpoint, Organon shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and distressed Altman Z-Score of 0.6 warrants caution. On valuation, the stock is attractively valued at 11.9x earnings, with trades above its Graham Number with a negative 26% margin. Growth dynamics show revenue growing at -5.3% and profit growth of -288.1%. Our composite FairStock Score of 52/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

The market underappreciates Organon's consistent 31% ROE at just 12x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $190 million in annual free cash flow (8.5% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer